Formulations of cross-linkable polymers capable of forming non-toxic and biocompatible hydrogels in situ containing at least one of doxycycline or minocycline. Methods of using the hydrogels for treating the skin or ocular tissues of mammals exposed to vesicant compounds such as sulfur mustard (SM) nitrogen mustard (NM) or half mustard (2-chloroethyl ethyl sulfide (CEES)) are also disclosed.

Disclosed is a method of treating melanoma in a mammal comprising administering (a) a therapeutically effective amount of an inhibitor of metabotropic glutamate receptor 1 (GRM1); and (b) a therapeutically effective amount of an inhibitor of at least one downstream signaling target of GRM1. Also disclosed are compositions and kits for treating melanoma comprising (a) a therapeutically effective amount of an inhibitor of GRM1; and (b) a therapeutically effective amount of an inhibitor of at least...

The present invention discloses the cloning of a new cDNA HGFIN from stimulated bone marrow stromal cells that was retrieved with a probe specific for the neurokinin-1 (NK-1) receptor. The novel gene HGFIN encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation. HGFIN is implicated in the treatment of hyperproliferative disorders particularly bone and breast cancer because it acts to suppress the proliferating cells.

The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells such as those of multiple myeloma and breast cancers. In particular immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced which are equipotent to anticancer agents used in free form but exhibit significantly redu...

Polymers (i.e. polyesters polyamides polythioesters polyanhydrides or a mixture thereof) which degrade hydrolytically to provide a combination of a beta-lactam antibiotic (e.g. amoxicillin) and a beta-lactamase inhibitor (e.g. clavulanic acid) (or a pharmaceutically acceptable salt thereof) are provided. Methods of producing these polymers intermediates useful for preparing these polymers and methods of using these polymers to deliver a combination of a beta-lactam antibiotic and a beta-lactamas...

Polymers (i.e. polyesters polyamides polythioesters polyanhydrides or a mixture thereof) which degrade hydrolytically to provide a combination of a beta-lactam antibiotic (e.g. amoxicillin) and a beta-lactamase inhibitor (e.g. clavulanic acid) (or a pharmaceutically acceptable salt thereof) are provided. Methods of producing these polymers intermediates useful for preparing these polymers and methods of using these polymers to deliver a combination of a beta-lactam antibiotic and a beta-lactamas...